Foghorn Therapeutics Inc.
Company Stats
- Market Cap
- $212.0M
- as of Sep 30, 2026
- Shares Outstanding
- 59.4M
- Free Float
- 66.9%
Income Statement
- Revenue
- $30.9M
- Operating Income
- -$86.4M
- Net Income
- -$74.3M
- EBITDA
- -$83.1M
- Revenue Growth, 3Y
- 17.1%
- FCF Margin, 3Y Avg
- -358.8%
- FCF Margin, Worst Year
- -448.2%
Cash Flow
- Free Cash Flow
- -$86.1M
- FCF Yield
- -40.6%
- Owner FCF Yield
- -45.5%
Balance Sheet
- Cash & Equivalents
- $80.9M
Returns & Capital
- SBC, 3Y Avg
- $12.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $30.9M | -$86.1M | -278.7% |
| FY2024 | $22.6M | -$101.3M | -448.2% |
| FY2023 | $34.2M | -$119.3M | -349.4% |
| FY2022 | $19.2M | $192.4M | 1000.6% |
| FY2021 | $1.3M | -$53.6M | -4060.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back